MARKET

RNXT

RNXT

Renovorx Inc
NASDAQ
1.110
+0.110
+11.00%
Pre Market: 1.120 +0.01 +0.90% 08:00 03/24 EDT
OPEN
0.9900
PREV CLOSE
1.000
HIGH
1.130
LOW
0.9800
VOLUME
2.80K
TURNOVER
77.02K
52 WEEK HIGH
1.450
52 WEEK LOW
0.7006
MARKET CAP
40.68M
P/E (TTM)
-2.5371
1D
5D
1M
3M
1Y
5Y
1D
RENOVORX ANNOUNCES CLOSING OF OVERSUBSCRIBED $10 MILLION AT MARKET PRIVATE PLACEMENT
Reuters · 1d ago
RenovoRx Raises $10 Million in Oversubscribed Private Placement
TipRanks · 1d ago
RenovoRx announces USD 10 million private placement of common stock and warrants
Reuters · 1d ago
Weekly Report: what happened at RNXT last week (0316-0320)?
Weekly Report · 1d ago
RenovoRx to host Q4 and full-year 2025 financial results conference call
Reuters · 4d ago
RenovoRx to Host Fourth Quarter and Full Year 2025 Financial Results and Business Highlights Conference Call on March 30th at 4:30 p.m. ET
Barchart · 4d ago
BUZZ-U.S. STOCKS ON THE MOVE-InspireMD, MiniMed, SoFi Technologies
Reuters · 5d ago
BUZZ-U.S. STOCKS ON THE MOVE-Tencent, Air Products, Protagonist
Reuters · 6d ago
More
About RNXT
RenovoRx, Inc. is a clinical and a commercial biopharmaceutical company. Its lead product RenovoCath a local drug delivery device, targeting high unmet medical needs. RenovoRx’s patented Trans-Arterial Micro-Perfusion (TAMP) therapy platform is designed to ensure targeted therapeutic delivery across the arterial wall near the tumor site to bathe the target tumor. RenovoRx’s novel approach to targeted treatment offers the potential for increased safety, tolerance, and improved efficacy, and to transform the lives of cancer patients by providing innovative solutions to enable targeted delivery of diagnostic and therapeutic agents. In addition to the RenovoCath device, RenovoRx is also evaluating the novel Phase III drug-device combination oncology product candidate (intra-arterial gemcitabine, known as IAG). The combination of intra-arterial infusion of chemotherapy, gemcitabine, and the RenovoCath device is being evaluated for the treatment of locally advanced pancreatic cancer.

Webull offers RenovoRx Inc stock information, including NASDAQ: RNXT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RNXT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading RNXT stock methods without spending real money on the virtual paper trading platform.